

## Editorial

**106** Aortic dissection—a contemporary revisit of an autopsy series

*Toru Suzuki, MD, PhD, Leicester and Leicester LE3 9QP, United Kingdom*

## Trial Designs

**1** Rationale and design of a randomized clinical trial to assess the safety and efficacy of multipoint pacing therapy: MOre REsponse on Cardiac Resynchronization Therapy with MultiPoint Pacing (MORE-CRT MPP-PHASE II)

*Christophe Leclercq, MD, PhD, Haran Burri, MD, Antonio Curnis, MD, PhD, Peter Paul Delnoy, MD, PhD, Christopher A Rinaldi, MD, PhD, Johannes Sperzel, MD, PhD, Kwangdeok Lee, PhD, Clay Cohorn, and Bernard Thibault, MD, PhD, on behalf of the MORE-RT MPP Investigators, CHU Pontchaillou Rennes, France; Geneva, Switzerland; Brescia, Italy; Zwolle, the Netherlands; London, United Kingdom; Bad Nauheim, Germany; Plano, TX; and Montreal, Canada*

**20** Immediate unselected coronary angiography versus delayed triage in survivors of out-of-hospital cardiac arrest without ST-segment elevation: Design and rationale of the TOMAHAWK trial

*Steffen Desch, MD, Anne Freund, MD, Tobias Graf, MD, Stephan Fichtlscherer, MD, Hendrik Haake, MD, Michael Preusch, MD, Fabian Hammer, MD, Ibrahim Akin, MD, Martin Christ, MD, Christoph Liebetrau, MD, Carsten Skurk, MD, Stephan Steiner, MD, Ingo Voigt, MD, Roland Schmitz, MD, Harald Mudra, MD, Jakob Ledwoch, MD, Niels Menck, MD, Jan Horstkotte, MD, Klaus Pels, MD, Anna-Lena Lahmann, MD, Sylvia Otto, MD, Karsten Lenk, MD, Marc-Alexander Ohlow, MD, Christian Hassager, MD, Peter Nordbeck, MD, Uwe Zeymer, MD, Alexander Jobs, MD, Suzanne de Waha-Thiele, MD, Denise Olbrich, PhD, Inke König, PhD, Kathrin Klinge, PhD, and Holger Thiele, MD, Lübeck, Leipzig, Frankfurt, Mönchengladbach, Heidelberg, Greifswald, Mannheim, Herne, Bad Nauheim, Berlin, Limburg, Essen, Bad Krozingen, München, Erfurt, Flensburg, Neumarkt, Jena, Bad Berka, Germany; Copenhagen, Denmark; Würzburg, and Ludwigshafen, Germany*

**88** Design and rationale of a randomized noninferiority trial to evaluate the SurVeil drug-coated balloon in subjects with stenotic lesions of the femoropopliteal artery — the TRANSCEND study

*Sammy Elmariyah, MD, MPH, Gary M. Ansel, MD, Marianne Brodmann, MD, Gheorghe Doros, PhD, Shawn Fuller, BS, William A. Gray, MD, Duane S. Pinto, MD, MPH, Kenneth A. Rosenfield, MD, MHCDS, and Laura Mauri, MD, Msc, Boston, MA; Columbus, OH; and Wynnewood, PA*

## Contents *continued*

### **97** Design and rationale of the Management of High Bleeding Risk Patients Post Bioresorbable Polymer Coated Stent Implantation With an Abbreviated Versus Standard DAPT Regimen (MASTER DAPT) Study

*Enrico Frigoli, MD, Pieter Smits, MD, Pascal Vranckx, MD, PhD, Yokio Ozaki, MD, PhD, Jan Tijssen, MD, PhD, Peter Jüni, MD, Marie-Claude Morice, MD, Yoshinobu Onuma, MD, PhD, Stephan Windecker, MD, André Frenk, PhD, Christian Spaulding, MD, Bernard Chevalier, MD, Emanuele Barbato, MD, PhD, Pim Tonino, MD, David Hildick-Smith, MD, Marco Roffi, MD, Ran Kornowski, MD, Carl Schultz, MD, PhD, Maciej Lesiak, MD, PhD, Andrés Iñiguez, MD, PhD, Antonio Colombo, MD, Mirvat Alasnag, MD, Ajit Mullasari, MD, Stefan James, MD, PhD, Goran Stankovic, MD, PhD, Paul J. L Ong, MD, Alfredo E Rodriguez, MD, PhD, Felix Mahfoud, MD, Jozef Bartunek, MD, PhD, Aris Moschovitis, MD, Peep Laanmets, MD, Sergio Leonardi, MD, Dik Heg, PhD, Mikael Sunnåker, PhD, and Marco Valgimigli, MD, PhD, Bern, Geneva, Switzerland; Rotterdam, Amsterdam, Eindhoven, the Netherlands; Hasselt, Aalst, Belgium; Aichi, Japan; Ontario, Canada; Massy, Paris, France; Naples, Italy; Brighton, United Kingdom; Tel Aviv, Israel; Perth, Australia; Poznan, Poland; Vigo, Spain; Milan, Pavia, Italy; Jeddah, Saudi Arabia; Chennai, India; Uppsala, Sweden; Belgrade, Serbia; Singapore, Singapore; Buenos Aires, Argentina; Homburg, Germany and Tallinn, Estonia*

#### **Policy Perspective**

### **116** How can clinical researchers quantify the value of their proposed comparative research?

*Anirban Basu, PhD, David L. Veenstra, PharmD, PhD, Josh J. Carlson, MPH, PhD, Weijih Wang, MS, Kelley Branch, MD, MS, and Jeffrey Probstfield, MD, FESC Seattle, WA*

#### **Clinical Investigations**

### **9** Significant mortality, morbidity and resource utilization associated with advanced heart failure in congenital heart disease in children and young adults

*Danielle S. Burstein, MD, Pirouz Shamszad, MD, Dingwei Dai, PhD, Christopher S. Almond, MD, Jack F. Price, MD, Kimberly Y. Lin, MD, Matthew J. O'Connor, MD, Robert E. Shaddy, MD, Christopher E. Mascio, MD, and Joseph W. Rossano, MD, Philadelphia, PA; Palo Alto, Los Angeles, CA; and Houston, TX*

### **29** New atrial fibrillation diagnosed by 30-day rhythm monitoring

*Gary Ross Farris, MD, Blake G. Smith, MD, Ethan T. Oates, MD, Chad Colon, MD, and Harish Doppalapudi, MD, Birmingham, AL*

### **36** Blood kidney injury molecule-1 predicts short and longer term kidney outcomes in patients undergoing diagnostic coronary and/or peripheral angiography—Results from the Catheter Sampled Blood Archive in Cardiovascular Diseases (CASABLANCA) study

*Nasrien E. Ibrahim, MD, Cian P. McCarthy, MB BCh BAO, Shreya Shrestha, MD, Asya Lyass, PhD, Yiwei Li, MS, Hanna K. Gaggin, MD, MPH, Mandy L. Simon, DNP NP, Joseph M. Massaro, PhD, Ralph B. D'Agostino, Sr, PhD, Joseph M. Garasic, MD, Roland RJ van Kimmenade, MD, PhD, and James L. Januzzi, Jr, MD, Boston, MA and Nijmegen, Netherlands*

### **47** A prospective 5-year study of exercise performance following Melody valve implant

*Bryant Priromprintr, MD, Michael J. Silka, MD, Jonathan Rhodes, MD, and Anjan S. Batra, MD, Los Angeles, Palo Alto, Irvine, CA; and Boston, MA*

### **54** Generalizability of the FOURIER trial to routine clinical care: Do trial participants represent patients in everyday practice?

*Xiaoxi Yao, PhD, Bernard J. Gersh, MB, ChB, DPhil, FRCP, Francisco Lopez-Jimenez, MD, Nilay D. Shah, PhD, and Peter A. Noseworthy, MD, Rochester and Cambridge, MA*

### **63** Comparison of the change in heart failure readmission and mortality rates between hospitals subject to hospital readmission reduction program penalties and critical access hospitals

*Alexander T. Sandhu, MD, MS, and Paul A. Heidenreich, MD, MS, Stanford, and Palo Alto, CA*

### **68** Vitamin D with calcium supplementation and risk of atrial fibrillation in postmenopausal women

*Brian C. Boursiquot, AB, Joseph C. Larson, MS, Omaima A. Shalash, PhD, Mara Z. Vitolins, DrPH, MPH, RDN, Elsayed Z. Soliman, MD, MSc, MS, and Marco V. Perez, MD, Stanford, CA; Seattle, WA; and Winston Salem, NC*

### **79** Differences in statin utilization and lipid lowering by race, ethnicity, and HIV status in a real-world cohort of persons with human immunodeficiency virus and uninfected persons

*Robert A. Riestenberg, BS, Andrew Furman, BA, Avery Cowen, BS, Anna Pawlowksi, MBA, Daniel Schneider, MS, Alana A. Lewis, MD, Sean Kelly, MD, Babafemi Taiwo, MBBS, Chad Achenbach, MD, MPH, Frank Palella, MD, Neil J. Stone, MD, Donald M. Lloyd-Jones, MD, ScM, and Matthew J. Feinstein, MD, MSc, Chicago, IL; Dallas, TX; and Nashville, TN*

## Contents *continued*

### **108** Clinical and pathologic findings of aortic dissection at autopsy: Review of 336 cases over nearly 6 decades

*Nick Huynh, MD, Sarah Thordsen, MD, Taylor Thomas, Shannon M. Mackey-Bojack, MD, Emily R. Duncanson, MD, Darlington Nwuado, Ross F. Garberich, MS, and Kevin M. Harris, MD, Minneapolis and St Paul, MN*

### **125** Development of a cardiac inherited disease service and clinical registry: A 15-year perspective

*Nikki J. Earle, PhD, Jackie Crawford, NZCS, Ian Hayes, MBChB, FRACP, Mark I. Rees, PhD, John French, MBChB, PhD, FRACP, Martin K. Stiles, MBChB, PhD, FRACP, Kathryn E. Waddell-Smith, MBChB, PhD, FRACP, Tom Donoghue, MNurs, RN, Rachael Monkley, PGDipNurs, RN, Katherine Neas, MBChB, FRACP, Andrew Aitken, MBChB, FRACP, Rexson Tse, MBBS, FRCPA, Donald R. Love, DSc, FRCPath, and Jonathan R. Skinner, MBChB, MD, FRACP, on Behalf of the Cardiac Inherited Diseases Group Auckland, Hamilton, Wellington, New Zealand; Swansea University, United Kingdom; New South Wales, Australia; and Doha, Qatar*

### **130** Spontaneous conversion in patients with non-valvular atrial fibrillation planned for electrical cardioversion: A subanalysis of the Edoxaban versus warfarin in subjects Undergoing cardioversion Of Atrial Fibrillation (ENSURE-AF) trial

*Ariel A. Cohen, Hein Heidbuchel, Jean-Yves Le Heuzey, Raffaele De Caterina, Jose L. Merino, James Jin, Michael Melino, Shannon M. Winters, Andreas Goette, and Gregory Y.H. Lip, France, Belgium, Chieti, Italy, Madrid, Spain, USA, Germany, and UK*